More News! Merck KGaA to drop Biosimilars? Sanofi buys into RSV

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Nick Bezuidenhout

  • Merck KGaA might jettison its biosimilar R&D program in the face of increasing competition
  • AstraZeneca will grant Sanofi access to its RSV program for the price of €120M
  • Actavis and Concordia are under scrutiny from a UK competition authority for ‘illegal’ deals

Sarine Arslanian

  • Merck KGaA presented positive Phase Ib results in psoriasis patients from a nanobody it picked up from Ablynx
  • Allergan received a green light to launch a new drug for night-time urination
  • Nicox resubmitted its NDA for reformulated Zyrtec, Zerviate

Forget the fox, what did the sloth say?


Images from Paul Strehlenert, Nick Bezuidenhout and Sarine Arslanian / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.